Last reviewed · How we verify
Pazopanib plus Gemcitabine
Pazopanib plus Gemcitabine is a Small molecule drug developed by North Eastern German Society of Gynaecological Oncology. It is currently in Phase 2 development. Also known as: Votrient and Gemzar.
At a glance
| Generic name | Pazopanib plus Gemcitabine |
|---|---|
| Also known as | Votrient and Gemzar |
| Sponsor | North Eastern German Society of Gynaecological Oncology |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Drug Screening Using Novel IMD in Renal Cell Carcinoma (PHASE1)
- Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents (PHASE2)
- Pazopanib Vs. Pazopanib Plus Gemcitabine (PHASE2)
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (PHASE1)
- Phase 3 Study to Treat Patients With Soft Tissue Sarcomas (PHASE3)
- High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NA)
- Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma (PHASE2)
- A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pazopanib plus Gemcitabine CI brief — competitive landscape report
- Pazopanib plus Gemcitabine updates RSS · CI watch RSS
- North Eastern German Society of Gynaecological Oncology portfolio CI
Frequently asked questions about Pazopanib plus Gemcitabine
What is Pazopanib plus Gemcitabine?
Pazopanib plus Gemcitabine is a Small molecule drug developed by North Eastern German Society of Gynaecological Oncology.
Who makes Pazopanib plus Gemcitabine?
Pazopanib plus Gemcitabine is developed by North Eastern German Society of Gynaecological Oncology (see full North Eastern German Society of Gynaecological Oncology pipeline at /company/north-eastern-german-society-of-gynaecological-oncology).
Is Pazopanib plus Gemcitabine also known as anything else?
Pazopanib plus Gemcitabine is also known as Votrient and Gemzar.
What development phase is Pazopanib plus Gemcitabine in?
Pazopanib plus Gemcitabine is in Phase 2.
Related
- Manufacturer: North Eastern German Society of Gynaecological Oncology — full pipeline
- Also known as: Votrient and Gemzar
- Compare: Pazopanib plus Gemcitabine vs similar drugs
- Pricing: Pazopanib plus Gemcitabine cost, discount & access